Want to see IN:ALPA full AI Analyst Report?
ALPA Stock Chart & Stats
₹75.60
-₹1.63(-1.24%)
At close: 4:00 PM EST
₹75.60
-₹1.63(-1.24%)
Day’s Range― - ―
52-Week Range₹46.00 - ₹100.00
Previous CloseN/A
Volume65.27K
Average Volume (3M)2.75K
Market Cap
₹1.31B
Enterprise Value₹473.12
Total Cash (Recent Filing)₹1.38B
Total Debt (Recent Filing)₹25.08M
Price to Earnings (P/E)36.6
Beta1.61
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.78
Shares Outstanding21,040,600
10 Day Avg. Volume3,648
30 Day Avg. Volume2,746
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.52
Price to Sales (P/S)0.92
P/FCF Ratio11.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal leverage reduces interest and refinancing pressure, giving Alpa greater resilience during weak operating periods and flexibility to fund production, working capital, or expansion without relying heavily on external debt.
Growing Equity BaseSteady equity accumulation indicates retained capital and supports asset growth. A larger capital base can strengthen solvency, absorb earnings volatility, and provide a durable foundation for the company’s pharmaceutical manufacturing operations.
Positive Operating Cash FlowRecurring positive operating cash flow shows the business can generate cash from operations over time. The 2026 improvement and positive free cash flow provide some internal funding capacity despite uneven cash conversion.
Bears Say
Latest-year Revenue DeclineThe latest revenue contraction signals inconsistent demand or execution in the domestic medicines market. Sustained weakness would limit operating leverage, reduce scale benefits, and make future earnings growth less predictable.
Sharp Margin CompressionSevere gross and operating margin deterioration indicates materially weaker core economics, whether from pricing, product mix, or costs. Persistently thin operating profit would leave limited protection against input inflation or competitive pressure.
Weak Earnings-to-cash ConversionLow cash conversion suggests working-capital drag or earnings supported by items that do not translate into cash. Volatile free cash flow also complicates planning and may constrain reliable reinvestment or shareholder distributions.
Alpa Laboratories Limited News
ALPA FAQ
What was Alpa Laboratories Limited’s price range in the past 12 months?
Alpa Laboratories Limited lowest stock price was ₹46.00 and its highest was ₹100.00 in the past 12 months.
What is Alpa Laboratories Limited’s market cap?
Alpa Laboratories Limited’s market cap is ₹1.31B.
When is Alpa Laboratories Limited’s upcoming earnings report date?
Alpa Laboratories Limited’s upcoming earnings report date is Nov 12, 2026 which is in 77 days.
How were Alpa Laboratories Limited’s earnings last quarter?
Alpa Laboratories Limited released its earnings results on Aug 13, 2026. The company reported ₹0.466 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Alpa Laboratories Limited overvalued?
According to Wall Street analysts Alpa Laboratories Limited’s price is currently Overvalued.
Does Alpa Laboratories Limited pay dividends?
Alpa Laboratories Limited does not currently pay dividends.
What is Alpa Laboratories Limited’s EPS estimate?
Alpa Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alpa Laboratories Limited have?
Alpa Laboratories Limited has 21,040,600 shares outstanding.
What happened to Alpa Laboratories Limited’s price movement after its last earnings report?
Alpa Laboratories Limited reported an EPS of ₹0.466 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.537%.
Which hedge fund is a major shareholder of Alpa Laboratories Limited?
Currently, no hedge funds are holding shares in IN:ALPA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alpa Laboratories Limited
Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-grade medications, encompassing ethical, generic, and over-the-counter varieties, available in diverse forms such as injections, tablets, capsules, eye and ear drops, ointments, creams, and gels. Furthermore, it supplies veterinary pharmaceuticals, including boluses, injections, and intra-mammary infusions. Its extensive product range addresses numerous therapeutic categories, including anti-infectives (covering antibacterials, antibiotics, antifungals, antiprotozoals, and antivirals), pain relievers, anti-inflammatory drugs, cold and cough remedies, cardiovascular treatments, anti-diabetic agents, nutritional supplements, psychotropic medicines, and specialized preparations for skin, ear, and eye care. Alpa Laboratories distributes its goods through a robust network comprising distributors, retail pharmacies, and hospitals. The company also extends its reach internationally, exporting its products to various regions across South and Central America, Africa, Asia, and the CIS countries.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Brooks Laboratories Limited
―
Nectar Lifesciences Ltd.
―
Par Drugs and Chemicals Limited
―

